Citigroup
PRAX icon

Citigroup’s Praxis Precision Medicines PRAX Stock Holding History

Citigroup’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-7,800
Closed -$295K – 5844
2025
Q1 		$295K Buy
7,800
+7,600
+3,800% +$475K ﹤0.01% 3962
2024
Q4 		$15.4K Buy
+200
New +$14.5K ﹤0.01% 5307

Other funds holding PRAX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Citigroup's PRAX Position: Q1 2026 in Review

Citigroup increased its Praxis Precision Medicines (PRAX) stake by 1.1% in Q1 2026, buying an estimated $18.6K and bringing the position to 5,646 shares worth $1.82M. The position accounts for ﹤0.01% of the portfolio, ranked #2721.

Citigroup first reported a position in PRAX in Q4 2020 and has held it in 22 quarters since. The position peaked at $7.31M in Q4 2024. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

  • Citigroup held 5,646 shares of Praxis Precision Medicines worth $1.82M as of Q1 2026.
  • Citigroup bought 60 Praxis Precision Medicines shares in Q1 2026, an estimated $18.6K.
  • Praxis Precision Medicines made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2721 holding.
  • Citigroup first reported a position in Praxis Precision Medicines in Q4 2020 and has held it in 22 quarters since.
  • Citigroup's Praxis Precision Medicines position peaked at $7.31M in Q4 2024.
  • 289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.